A Double-Blind, Placebo-Controlled, Randomised, Two Part Study of the Safety and Pharmacokinetics of GMC-252 in A) Healthy Male Subjects, Including a Comparison of GMC-252 Dosing in the Fed and Fasted States ,and B) in Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 06 Nov 2021
At a glance
- Drugs GMC 252 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Genmedica Therapeutics
- 25 Feb 2016 New trial record